Mumbai, May 13 (IANS). Pharma company Cipla on Wednesday released the results of the fourth quarter (Q4) of the financial year 2025-26, in which the company’s consolidated net profit declined by 54.6 percent to Rs 554.64 crore. This big decline in the company’s profit was due to impairment charges, while the company’s income also recorded a slight decline on an annual basis.
In the stock exchange filing, the company said that the net profit of the company in the January-March quarter stood at Rs 554.64 crore, whereas in the same quarter of the last financial year it was Rs 1,221.84 crore.
The company’s income from operations in the fourth quarter was Rs 6,541.20 crore, which was Rs 6,729.69 crore in the same period last year. Thus a decline of 2.80 percent was recorded in revenue.
At the operational level, the company’s EBITDA also declined by 38 percent to Rs 955 crore, which was Rs 1,537.6 crore in the same quarter of the last financial year.
At the same time, EBITDA margin also declined from 22.80 percent to 14.6 percent on an annual basis.
Cipla said that during the quarter and full financial year ended March 31, 2026, the company recorded an impairment charge of Rs 42.02 crore in its subsidiaries due to certain business circumstances and changes in market dynamics.
The company said that if the impact of impairment charge was removed, EBITDA in the fourth quarter would have been Rs 997 crore and EBITDA margin would have been 15.2 percent.
Meanwhile, the company’s board of directors has recommended a final dividend of Rs 13 per equity share for the financial year 2025-26.
The company said the dividend will be paid within 30 days from the date of the Annual General Meeting (AGM) after getting the approval of the shareholders.
Also, the company has declared June 5, 2026 as the record date to identify the shareholders eligible for the final dividend.
After the quarterly results, there was a rise in the shares of Cipla in the stock market. Till the time of writing the news, around 2:40 pm, the company’s shares were seen trading at Rs 1,338.10 on NSE with a gain of 3.5 percent.
–IANS
DBP
